OEM News

Zimmer Biomet Wins FDA Nod for Oxford Cementless Partial Knee

According to Zimmer Biomet, it's the only cementless partial knee replacement implant in the U.S.

Author Image

By: Sam Brusco

Associate Editor

Zimmer Biomet has earned U.S. Food and Drug Administration (FDA) approval for its Oxford cementless partial knee.

According to Zimmer Biomet, the Oxford knee lets surgeons perform a partial knee replacement (PKR) with improved fixation, better long-term implant survival rate, and more efficiency in the OR compared to the Oxford cemented partial knee procedure.

After over 20 years of clinical experience and 300,000 procedures in Canada, Europe, the Middle East, Africa, and Asia, the Oxford cementless partial knee is now the only FDA-approved cementless partial knee implant in the U.S. The approval was based on data from an investigational device exemption (IDE) and non-clinical testing for cementless PKR.

The new Oxford knee has a mobile bearing that moves with the femoral component through the entire range of motion to mimic natural movement of the knee. The design, according to Zimmer Biomet, provides better range of motion, a more natural feel, and more stable implant-to-bone fixation.

The system’s tibial and femoral components have a titanium and hydroxyapatite coating to promote osseointegration. The UK national joint registry has more than 33,000 patients treated with Oxford Cementless Partial Knees recorded with a 94.1% rate of implant survival at 10 years after surgery,3 which is higher than the average 10-year survivorship for all other partial knees (89.9%).

“For younger and more active patients, the Oxford Cementless Partial Knee amplifies the benefits of a traditional partial knee replacement by offering knee flexion that resembles natural knee movement, and stronger adhesion of the implant to the bone for better long-term durability,” said Adolph V. Lombardi Jr., MD, FACS, President of JIS Orthopedics in New Albany, Ohio. “In my own practice, a cementless approach has increased OR efficiency by shortening my surgery time and reducing costs associated with cement preparation.”

As part of its nationwide U.S. launch in Q1 2025, Zimmer Biomet will offer FDA-required training that focuses on the cementless surgical technique and proper selection of patients.

“Cementless knee replacement procedures are increasingly preferred by surgeons seeking to improve surgical efficiency. The Oxford Cementless Partial Knee is coming into the U.S. with a proven track record of retaining more healthy anatomy with a less invasive approach and improved outcomes6 as compared to a total knee replacement,” said Joe Urban, President, Knees at Zimmer Biomet. “We are excited to address the unmet U.S. demand for a cementless partial knee with a new offering which has 20 years of clinical experience in more than 50 countries.”

Keep Up With Our Content. Subscribe To Orthopedic Design & Technology Newsletters